Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
ALEMBIC | SANOFI INDIA | ALEMBIC/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 59.1 | 42.5 | 139.0% | View Chart |
P/BV | x | 5.1 | 8.7 | 58.9% | View Chart |
Dividend Yield | % | 0.2 | 1.0 | 19.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
SANOFI INDIA Dec-18 |
ALEMBIC/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 6,840 | 1.1% | |
Low | Rs | 34 | 4,630 | 0.7% | |
Sales per share (Unadj.) | Rs | 4.7 | 1,203.1 | 0.4% | |
Earnings per share (Unadj.) | Rs | 6.1 | 165.3 | 3.7% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 209.9 | 3.0% | |
Dividends per share (Unadj.) | Rs | 0.20 | 84.00 | 0.2% | |
Dividend yield (eoy) | % | 0.4 | 1.5 | 25.8% | |
Book value per share (Unadj.) | Rs | 40.7 | 963.6 | 4.2% | |
Shares outstanding (eoy) | m | 267.03 | 23.03 | 1,159.5% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 11.3 | 4.8 | 236.3% | |
Avg P/E ratio | x | 8.7 | 34.7 | 25.0% | |
P/CF ratio (eoy) | x | 8.5 | 27.3 | 31.0% | |
Price / Book Value ratio | x | 1.3 | 6.0 | 21.9% | |
Dividend payout | % | 3.3 | 50.8 | 6.4% | |
Avg Mkt Cap | Rs m | 14,139 | 132,078 | 10.7% | |
No. of employees | `000 | NA | 3.3 | 0.0% | |
Total wages/salary | Rs m | 207 | 4,068 | 5.1% | |
Avg. sales/employee | Rs Th | NM | 8,393.8 | - | |
Avg. wages/employee | Rs Th | NM | 1,232.4 | - | |
Avg. net profit/employee | Rs Th | NM | 1,153.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 27,708 | 4.5% | |
Other income | Rs m | 370 | 897 | 41.3% | |
Total revenues | Rs m | 1,625 | 28,605 | 5.7% | |
Gross profit | Rs m | 111 | 6,235 | 1.8% | |
Depreciation | Rs m | 38 | 1,027 | 3.7% | |
Interest | Rs m | 2 | 7 | 24.3% | |
Profit before tax | Rs m | 442 | 6,098 | 7.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 2,292 | 1.0% | |
Profit after tax | Rs m | 1,630 | 3,806 | 42.8% | |
Gross profit margin | % | 8.9 | 22.5 | 39.3% | |
Effective tax rate | % | 5.4 | 37.6 | 14.4% | |
Net profit margin | % | 129.8 | 13.7 | 945.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 15,922 | 11.7% | |
Current liabilities | Rs m | 591 | 6,235 | 9.5% | |
Net working cap to sales | % | 101.6 | 35.0 | 290.7% | |
Current ratio | x | 3.2 | 2.6 | 123.7% | |
Inventory Days | Days | 94 | 64 | 148.1% | |
Debtors Days | Days | 74 | 21 | 352.4% | |
Net fixed assets | Rs m | 1,791 | 7,539 | 23.8% | |
Share capital | Rs m | 534 | 230 | 232.2% | |
"Free" reserves | Rs m | 10,324 | 21,962 | 47.0% | |
Net worth | Rs m | 10,858 | 22,192 | 48.9% | |
Long term debt | Rs m | 41 | 0 | - | |
Total assets | Rs m | 11,591 | 29,839 | 38.8% | |
Interest coverage | x | 260.9 | 872.1 | 29.9% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.1 | 0.9 | 11.7% | |
Return on assets | % | 14.1 | 12.8 | 110.2% | |
Return on equity | % | 15.0 | 17.2 | 87.5% | |
Return on capital | % | 15.2 | 27.5 | 55.2% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 21.0 | 0 | - | |
Exports (fob) | Rs m | 19 | NA | - | |
Imports (cif) | Rs m | 263 | NA | - | |
Fx inflow | Rs m | 19 | 7,587 | 0.3% | |
Fx outflow | Rs m | 264 | 7,145 | 3.7% | |
Net fx | Rs m | -244 | 442 | -55.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 3,739 | 6.3% | |
From Investments | Rs m | -224 | -731 | 30.6% | |
From Financial Activity | Rs m | -27 | -1,972 | 1.3% | |
Net Cashflow | Rs m | -15 | 1,036 | -1.4% |
Indian Promoters | % | 64.0 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 0.2 | 14.4 | 1.4% | |
FIIs | % | 9.7 | 14.6 | 66.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 10.5 | 248.6% | |
Shareholders | 54,701 | 15,184 | 360.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: STERLING BIOTECH NOVARTIS ALEMBIC PHARMA ORCHID PHARMA PFIZER
Compare ALEMBIC With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More